Dana-farber-cancer Institute Inc.

Oregon Health & Science University

The Brigham and Women's Hospital, Inc.

The United States Government As Represented by the Department of Veterans Affairs

Novartis Ag

George Daniel Demetri

Jonathan A Fletcher

Michael C Heinrich

Christopher C Corless

Brian Jay Druker

Elisabeth Buchdunger

Sandra Leta Silberman

Heikki Joensuu

Sasa Dimitrijevic

David Tuveson

Renaud Capdeville

This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.

Platelet derived growth factor receptor alpha (PDGFRA) polypeptides comprising activating mutation(s)

Nucleic acids encoding platelet derived growth factor receptor alpha (PDGFRA) activating mutations

Method of detecting a neoplasia associated with an activating platelet derived growth factor receptor alpha (PDGFRA) mutation

4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula Ior a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.

Treatment of gastrointestinal stromal tumors

Growing community of inventors

Brookline, MA, United States of America

George Daniel Demetri